|SEND TO PRINTER|
GEN News Highlights : Oct 15, 2009
Pikamab Secures Patents that Will Enable Development of Theranostic for Lupus
Firm hopes to have CLIA-certified Lupus Therasight test available in 2010.
Pikamab negotiated exclusive rights to two U.S. patents held by New York’s Hospital for Special Surgery relating to technologies for determining the occurrence, susceptibility patterns, and severity of lupus and lupus nephritis. The patents are relevant to Pikamab’s theranostic product, Lupus Therasight™, which is being designed to help guide drug development and patient treatment protocols.
Then in March Genentech and Biogen Idec confirmed that a Phase III trial combining Rituxan® with mycophenolate mofetil (MMF) and corticosteroids in lupus nephritis patients failed to significantly reduce disease activity at 52 weeks.
Within the last few months things have started looking up, however. In July Human Genome Sciences and GlaxoSmithKline reported positive results from the first of two Phase III trials with Benlysta in patients with serologically active systemic lupus erythematosus (SLE). Results from the second Phase III trial are expected in November. The companies say that if this trial is also positive, they project submitting marketing applications in the U.S., Europe, and other regions during the first half of 2010.
© 2012 Genetic Engineering & Biotechnology News, All Rights Reserved